TY - JOUR
T1 - Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod
T2 - A Case Report and Brief Literature Review
AU - Drohan, Ashley
AU - Vidovic, Dejan
AU - Barnes, Penelope Jane
AU - Giacomantonio, Carman Anthony
AU - Helyer, Lucy Kathryn
N1 - Publisher Copyright:
Copyright © 2022 Drohan, Vidovic, Barnes, Giacomantonio and Helyer.
PY - 2022/5/30
Y1 - 2022/5/30
N2 - Breast cancer is the most common non-cutaneous cancer affecting women worldwide and is a major cause of cancer-related morbidity and mortality in females. While many women are diagnosed with early-stage disease, a subset of women may present with isolated cutaneous metastases or recurrent locoregional cutaneous metastatic disease. There is a paucity of evidence for effective treatments for cutaneous breast cancer metastases. Herein, we present a case of hormone receptor negative, HER2 positive cutaneous breast cancer metastasis treated with intralesional IL-2 and topical imiquimod, which was well tolerated with only minor low grade side effects. We also present a brief literature review of immunotherapy for cutaneous breast cancer metastasis to frame the discussion around using minimally invasive local therapies for this disease. Together, this limited data suggests that intralesional IL-2 and imiquimod may be considered as a safe option when treating a patient with cutaneous breast cancer metastases.
AB - Breast cancer is the most common non-cutaneous cancer affecting women worldwide and is a major cause of cancer-related morbidity and mortality in females. While many women are diagnosed with early-stage disease, a subset of women may present with isolated cutaneous metastases or recurrent locoregional cutaneous metastatic disease. There is a paucity of evidence for effective treatments for cutaneous breast cancer metastases. Herein, we present a case of hormone receptor negative, HER2 positive cutaneous breast cancer metastasis treated with intralesional IL-2 and topical imiquimod, which was well tolerated with only minor low grade side effects. We also present a brief literature review of immunotherapy for cutaneous breast cancer metastasis to frame the discussion around using minimally invasive local therapies for this disease. Together, this limited data suggests that intralesional IL-2 and imiquimod may be considered as a safe option when treating a patient with cutaneous breast cancer metastases.
UR - http://www.scopus.com/inward/record.url?scp=85132273582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132273582&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.877014
DO - 10.3389/fonc.2022.877014
M3 - Article
C2 - 35712509
AN - SCOPUS:85132273582
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 877014
ER -